<?xml version="1.0" encoding="UTF-8"?>
<p>A new two-dose HBV vaccine was recently approved by the United States Food and Drug Administration (FDA) and is already recommended by Advisory Committee on Immunization Practices (ACIP) for individuals &gt;18â€‰years. This vaccine includes a novel oligonucleotide adjuvant that activates the toll-like receptor 9 (TLR-9) pathway and has been shown to have higher vaccine efficacy compared with recombinant vaccine, even in difficult populations, such as patients with diabetes.
 <sup>
  <xref rid="bibr115-1759720X20912646" ref-type="bibr">115</xref>,
  <xref rid="bibr116-1759720X20912646" ref-type="bibr">116</xref>
 </sup> To date, data on the efficacy and safety of this novel vaccine in rheumatic patients are lacking.
</p>
